TA1 — Peptide Dosing Protocols reference

patient_educationexpert_opinion · status: needs_provider_review

Details

Author: —

Citation: —

Summary (generated — provider review required)

Thymosin Alpha-1 (TA1) Peptide Guide: Dosage, Reconstitution & Side Effects Shop Protocols Stacks A–Z Index Email Updates Home Protocols Thymosin Alpha-1 (TA1) Peptide Guide: Dosage, Reconstitution & Side Effects Protocol / Research Dosing Guide Thymosin Alpha-1 (TA1) Peptide Guide: Dosage, Reconstitution & Side Effects Plain-language Thymosin Alpha-1 (TA1, Zadaxin / thymalfasin) research dosing guide covering the standard 1.6 mg twice-weekly schedule, reconstitution math, supplies by cycle length, side effects, and current US regulatory status. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners Thymosin Alpha-1 Supply View supply Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Thymosin Alpha-1 Comparisons Related Protocols Blood Tests FAQ References Thymosin Alpha-1 Quick Start Thymosin Alpha-1 (TA1) is a 28-amino-acid peptide your thymus gland naturally makes. It helps train and coordinate the immune cells that fight viruses and other infections.

The original source document remains the source of truth. Generated summaries are not authoritative.

Linked assets (16) · phenotypes (0)

evidence_reference, dosing_reference, mechanism, monitoring_reference, safety_reference

Findings (154) · awaiting review (117)

mechanism · pending

The pathway is well-mapped.

dosing · pending

By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners Thymosin Alpha-1 Supply View supply Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Thymosin Alpha-1 Comparisons Related Protocols Blood Tests FAQ References Thymosin Alpha-1 Quick Start Thymosin Alpha-1 (TA1) is a 28-amino-acid peptide your thymus gland naturally makes.

regulatory · pending

The synthetic version, thymalfasin , is sold under the brand name Zadaxin and is approved in more than 35 countries for chronic hepatitis B, chronic hepatitis

regulatory · pending

It is not FDA-approved in the United States and is currently being reviewed for inclusion on the 503A bulk drug substances list.

dosing · pending

TA1 is given by subcutaneous injection .

dosing · pending

The standard clinical schedule, validated in chronic hepatitis B trials, is 1.6 mg twice weekly for 6 to 12 months.

dosing · pending

Route Subcutaneous (under the skin) - abdomen, thigh, or upper arm.

dosing · pending

Standard schedule 1.6 mg twice weekly, 3-4 days apart (e.g., Monday and Thursday).

dosing · pending

Measure From a 10 mg vial reconstituted with 2 mL bacteriostatic water (5 mg/mL), 1.6 mg = 0.32 mL = 32 units on a U-100 insulin syringe.

regulatory · pending

Thymosin Alpha-1 is not FDA-approved in the United States.

dosing · pending

Thymosin Alpha-1 Dosing Protocol & Schedule Almost every published TA1 dose traces back to one core protocol: 1.6 mg subcutaneously twice weekly .

dosing · pending

That's the dose used across the chronic hepatitis B and C trials that won Zadaxin its international approvals, and it's the dose adopted in most cancer adjunct, severe sepsis, and immune-support studies that came after.

dosing · pending

Standard adult Adult under 40 kg The Zadaxin-anchored 1.6 mg twice-weekly protocol used in chronic HBV, HCV, and most cancer-adjunct trials.

dosing · pending

Standard adult dosing is 1.6 mg subcutaneously twice weekly , with injections spaced 3 to 4 days apart.

dosing · pending

Standard adult dosing protocol Parameter Dose per injection Value 1.6 mg Parameter Frequency Value Twice weekly Parameter Spacing Value 3-4 days apart (e.g., Mon/Thu) Parameter Route Value Subcutaneous Parameter Typical duration Value 6 months (HBV monotherapy / cancer adjunct); up to 12 months (HCV combination) Parameter Value Dose per injection 1.6 mg Frequency Twice weekly Spacing 3-4 days apart (e.g., Mon/Thu) Route Subcutaneous Typical duration 6 months (HBV monotherapy / cancer adjunct); up to 12 months (HCV combination) Source: published Zadaxin/thymalfasin pooled analyses for chronic hepatitis B and C.

dosing · pending

For adults weighing under 40 kg (88 lb), the labeled adjustment is 40 mcg/kg twice weekly , subcutaneous.

dosing · pending

Body-weight-adjusted dosing (under 40 kg) Body weight 30 kg Approximate dose 1.2 mg twice weekly Body weight 35 kg Approximate dose 1.4 mg twice w

dosing · pending

eekly Body weight ≥40 kg Approximate dose 1.6 mg twice weekly (standard adult) Body weight Approximate dose 30 kg 1.2 mg twice weekly 35 kg 1.4 mg twice weekly ≥40 kg 1.6 mg twice weekly (standard adult) Source: Zadaxin professional monograph dosing guidance for adults under 40 kg.

dosing · pending

g Community protocols (e.g., 1 mg daily for 10-30 days for immune loading) appear widely online but are not drawn from controlled trials.

dosing · pending

Peptide Dosing Protocols documents the published clinical schedule first and treats community use as commentary, not protocol guidance.

dosing · pending

Thymosin Alpha-1 Supplies Needed Plan based on the standard 1.6 mg twice-weekly schedule using a 10 mg vial reconstituted with 2 mL bacteriostatic water (5 mg/mL), which yields 6 doses per vial (1.6 mg x 6 = 9.6 mg).

dosing · pending

Peptide Vials Each 10 mg vial reconstituted with 2 mL BAC water yields about 6 doses at 1.6 mg.

dosing · pending

Cycle length Planning note 4 weeks 2 vials 8 doses needed; 1 vial gives 6 doses, 2 vials give 12 (margin for losses).

dosing · pending

8 weeks 3 vials 16 doses needed; 3 vials give 18 doses with margin.

dosing · pending

12 weeks 4 vials 24 doses needed; 4 vials give 24 doses exactly - round up to 5 if you want margin.

dosing · pending

52 doses needed; 9 vials give 54 doses with margin.

dosing · pending

4 weeks 2 vials 8 doses needed; 1 vial gives 6 doses, 2 vials give 12 (margin for losses).

dosing · pending

8 weeks 3 vials 16 doses needed; 3 vials give 18 doses with margin.

dosing · pending

12 weeks 4 vials 24 doses needed; 4 vials give 24 doses exactly - round up to 5 if you want margin.

dosing · pending

26 weeks (HBV course) 9 vials 52 doses needed; 9 vials give 54 doses with margin.

dosing · pending

Insulin Syringes (U-100, 0.5 mL preferred) 1.6 mg from a 5 mg/mL vial = 0.32 mL = 32 units, which fits a 0.5 mL / 50-unit syringe cleanly.

dosing · pending

Bacteriostatic Water Each 10 mg vial uses 2 mL BAC water for reconstitution.

dosing · pending

hanges that build up over weeks of repeated dosing.

dosing · pending

Cycle length Planning note 4-26 weeks 1 x 30 mL bottle 4 weeks: 2 vials use 4 mL total; one bottle is plenty.; 8 weeks: 3 vials use 6 mL total; one bottle is plenty.; 12 weeks: 4 vials use 8 mL total; one bottle is plenty.; 26 weeks: 9 vials use 18 mL total; one bottle is plenty.

dosing · pending

4-26 weeks 1 x 30 mL bottle 4 weeks: 2 vials use 4 mL total; one bottle is plenty.; 8 weeks

dosing · pending

: 3 vials use 6 mL total; one bottle is plenty.; 12 weeks: 4 vials use 8 mL total; one bottle is plenty.; 26 weeks: 9 vials use 18 mL total; one bottle is plenty.

dosing · pending

Thymosin Alpha-1 Reconstitution Guide TA1 ships as a lyophilized (freeze-dried) powder in vial sizes of 5 mg, 10 mg, and 20 mg.

dosing · pending

The table below shows the most common vial-to-BAC-water combinations and what each one means for drawing a 1.6 mg dose on a U-100 insulin syringe.

safety · pending

Human safety data in pregnancy and lactation is limited.

Processing

Processed into 29 searchable sections.